A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.

Trial Profile

A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 13 Jan 2017 Status changed from active, no longer recruiting to discontinued.
    • 23 Jan 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2025 as reported in the ClinicalTrials.gov record.
    • 06 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported in the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top